Drug
Byetta, Exenatide
Byetta, Exenatide is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_4
2
50%
Ph phase_3
1
25%
Ph phase_2
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 42 (50.0%)
Trials by Status
completed375%
unknown125%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects
NCT00856609
completedphase_4
The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes
NCT00950677
unknownphase_4
Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function
NCT02584075
completedphase_2
The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET
NCT00747968
Clinical Trials (4)
Showing 4 of 4 trials
NCT00856609Phase 3
The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects
NCT00950677Phase 4
The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes
NCT02584075Phase 4
Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function
NCT00747968Phase 2
The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4